Cassava Sciences Inc (SAVA)
21.38
+0.64
(+3.09%)
USD |
NASDAQ |
Apr 25, 12:40
Cassava Sciences Research and Development Expense (Quarterly): 18.73M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 18.73M |
| September 30, 2023 | 23.60M |
| June 30, 2023 | 24.97M |
| March 31, 2023 | 22.12M |
| December 31, 2022 | 17.65M |
| September 30, 2022 | 18.53M |
| June 30, 2022 | 16.95M |
| March 31, 2022 | 14.91M |
| December 31, 2021 | 10.34M |
| September 30, 2021 | 8.041M |
| June 30, 2021 | 3.901M |
| March 31, 2021 | 2.529M |
| December 31, 2020 | 1.519M |
| September 30, 2020 | 0.399M |
| June 30, 2020 | 0.591M |
| March 31, 2020 | 0.544M |
| December 31, 2019 | 0.738M |
| September 30, 2019 | -0.052M |
| June 30, 2019 | 0.308M |
| March 31, 2019 | 0.574M |
| December 31, 2018 | 0.002M |
| September 30, 2018 | 0.436M |
| June 30, 2018 | 1.463M |
| March 31, 2018 | 1.068M |
| December 31, 2017 | 1.544M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.619M |
| June 30, 2017 | 3.063M |
| March 31, 2017 | 1.388M |
| December 31, 2016 | 1.335M |
| September 30, 2016 | 2.657M |
| June 30, 2016 | 1.589M |
| March 31, 2016 | 3.595M |
| December 31, 2015 | 3.62M |
| September 30, 2015 | 2.356M |
| June 30, 2015 | 1.986M |
| March 31, 2015 | 1.138M |
| December 31, 2014 | 1.108M |
| September 30, 2014 | 2.116M |
| June 30, 2014 | 1.935M |
| March 31, 2014 | 2.147M |
| December 31, 2013 | 1.151M |
| September 30, 2013 | 1.444M |
| June 30, 2013 | 1.139M |
| March 31, 2013 | 1.183M |
| December 31, 2012 | 2.101M |
| September 30, 2012 | 2.379M |
| June 30, 2012 | 1.516M |
| March 31, 2012 | 1.609M |
| December 31, 2011 | 1.711M |
| September 30, 2011 | 2.019M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.052M
Minimum
Sep 2019
24.97M
Maximum
Jun 2023
9.806M
Average
8.041M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Amylyx Pharmaceuticals Inc | 44.91M |
| MannKind Corp | 9.236M |
| Clearside Biomedical Inc | 6.313M |
| Lantern Pharma Inc | 3.573M |
| NovaBay Pharmaceuticals Inc | 0.004M |